<DOC>
	<DOCNO>NCT02364713</DOCNO>
	<brief_summary>This randomized phase II trial study well oncolytic measles virus encode thyroidal sodium iodide symporter ( MV-NIS ) compare investigator 's choice chemotherapy work treat patient ovarian , fallopian , peritoneal cancer . Measles virus , change certain way , may able kill tumor cell without damage normal cell .</brief_summary>
	<brief_title>MV-NIS Investigator 's Choice Chemotherapy Treating Patients With Ovarian , Fallopian , Peritoneal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare clinical efficacy Arm A ( MV-NIS therapy ) Arm B ( standard cytotoxic chemotherapy ) , measure overall survival ( OS ) . SECONDARY OBJECTIVES : I . Compare progression-free survival ( PFS ) , overall survival 12 month ( OS12 ) , progression-free survival six month ( PFS6 ) , objective response rate ( ORR ) MV-NIS therapy standard chemotherapy . III . Assess safety tolerability MV-NIS , compare standard chemotherapy . IV . Compare quality life assess Functional Assessment Cancer Therapy-Ovarian ( FACT-O ) MV-NIS standard chemotherapy . TERTIARY OBJECTIVES : I. Assess time course viral gene expression virus elimination biodistribution virally infected cell various time point infection MV-NIS use single-photon emission computerize tomography ( SPECT ) /computed tomography ( CT ) image within MV-NIS treatment arm . II . Assess viremia , viral replication , viral shedding/persistence follow intraperitoneal administration within NV-NIS treatment arm . III . Measure humoral cellular immune response MV-NIS within NV-NIS treatment arm . IV . Measure change anti-ovarian cancer ( OC ) immune response treatment arm . V. Perform transcriptomic analysis tumor biopsy specimens determine gene expression profile predictive therapeutic response MV-NIS . OUTLINE : Patients randomize 1 2 treatment arm . ARM A : Patients receive oncolytic measles virus encode thyroidal sodium iodide symporter intraperitoneally ( IP ) 30 minute day 1 . Courses repeat every 28 day absence disease progression unacceptable toxicity . ARM B : Patients receive pegylated liposomal doxorubicin hydrochloride intravenously ( IV ) 1 hour day 1 , gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 , topotecan hydrochloride IV 30 minute day 1 , 8 , 15 , paclitaxel IV 1 hour day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3-6 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>PREREGISTRATION INCLUSION CRITERIA : Ability understand willingness sign write informed consent document Study participant woman go bilateral oophorectomy procedure Willingness evaluate surgical placement intraperitoneal port undergo biopsy feasible research sample REGISTRATION/RANDOMIZATION INCLUSION CRITERIA : Recurrent , persistent , progressive epithelial ovarian , fallopian tube , primary peritoneal cancer treatment bilateral oophorectomy either cisplatin carboplatin either paclitaxel , albuminbound paclitaxel , docetaxel ; histologic confirmation primary tumor require ; eligible histology include serous , endometrioid , clear cell , mucinous , transitional cell , undifferentiated , mixed carcinoma Platinumresistant platinumrefractory disease , define either 1 ) less complete response recent carboplatin cisplatincontaining chemotherapy regimen , 2 ) serum cancer antigen ( CA ) 125 &gt; = 2 x upper limit normal ( ULN ) within 180 day last dose carboplatin cisplatincontaining chemotherapy , confirm second CA125 ( second CA125 within 180 day chemotherapy ) , 3 ) CT positron emission tomography ( PET ) /CT evidence cancer recurrence within 180 day last dose carboplatin cisplatincontaining chemotherapy Absolute neutrophil count ( ANC ) &gt; = 1500/uL Platelet ( PLT ) &gt; = 100,000/uL Total bilirubin = &lt; ULN Aspartate aminotransferase ( AST ) = &lt; 2 x ULN Creatinine = &lt; 1.5 x ULN Hemoglobin ( Hgb ) &gt; = 9.0 g/dL Willingness return Mayo Clinic Rochester another participate institution followup ; patient randomize Arm B ( cytotoxic chemotherapy ) may receive chemotherapy oncology clinic able provide protocoldirected therapy willing send laboratory data participate institution ; however , patient must willing return participate institution every two month evaluation ; patient randomize Arm A must willing receive treatment followup participate institution Life expectancy &gt; = 12 week Willingness provide biologic specimen require protocol Measurable disease physical exam CT scan , evaluable disease CA125 ; ( NOTE : CA125evaluable disease define serum CA125 &gt; = 2 x ULN determine treat clinician due recurrent ovarian , fallopian tube , primary peritoneal cancer ) Normal cardiac function , determine leave ventricular ejection fraction ( LVEF ) &gt; = institutional low limit normal echocardiogram multigated acquisition scan ( MUGA ) within 1 month registration If liposomal doxorubicin hydrochloride ( DOXIL ) select investigator 's choice chemotherapy : Lifetime exposure doxorubicin = &lt; 240 mg/m^2 ( equivalent biologic dose prior exposure different anthracycline ) Candidate surgical placement intraperitoneal port , determine gynecologic oncology surgeon Must antimeasles immunity demonstrate serum immunoglobulin ( Ig ) G antimeasles antibody level &gt; = 1.1 EU/ml determine BioPlex Measles IgG multiplex flow immunoassay REGISTRATION/RANDOMIZATION EXCLUSION CRITERIA : Epithelial tumor low malignant potential , stromal tumor , germ cell tumor ovary Evidence cancer outside peritoneal cavity ( ex : mediastinal lymphadenopathy , parenchymal liver metastasis , pleural effusion proven suspect due cancer ) Bulky metastasis , define tumor nodule lymph node &gt; 2 cm great dimension axial image pretreatment CT , PET/CT , magnetic resonance imaging ( MRI ) Note : patient bulky ( &gt; 2 cm ) disease gross total cytoreduction deem feasible surgeon ( confirmation second surgeon radiologic review ) eligible participation context cytoreductive surgery Resistant following : DOXIL , gemcitabine hydrochloride ( GEM ) , topotecan hydrochloride ( TOPA ) , weekly paclitaxel ( TAXOL ) ; ( NOTE : resistance define either 1 ) less complete response chemotherapy regimen contain agent question [ consider weekly TAXOL separate agent everythreeweek TAXOL ] , 2 ) serum CA125 &gt; = 2 x ULN within 180 day last dose chemotherapy contain agent question , confirm second CA125 [ second CA125 within 180 day chemotherapy ] , 3 ) CT PET/CT evidence cancer recurrence/progression within 180 day last dose chemotherapy contain agent question ; [ example , patient previously receive carboplatin GEM , complete response , initial evidence relapse &gt; 180 day last dose GEM , patient would consider resistant GEM ] ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 3 4 History malignancy = &lt; 5 year prior registration except nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ ( DCIS ) Active infection = &lt; 7 day prior study entry Any follow prior therapy : Chemotherapy = &lt; 3 week prior study entry Immunotherapy = &lt; 4 week prior study entry Biologic therapy = &lt; 4 week prior study entry Extensive abdominal surgery include enterotomy ( y ) = &lt; 3 week prior study entry ; ( NOTE : criterion apply placement peritoneal PortACath lysis adhesion time study entry ) Any viral gene therapy prior study entry Failure recover = &lt; grade 1 acute , reversible effect prior chemotherapy , exclude alopecia regardless interval since last treatment ( NOTE : patient residual peripheral neuropathy allow ) New York Heart Association classification III IV congestive heart failure , know symptomatic coronary artery disease , symptom coronary artery disease system review , know cardiac arrhythmia ( atrial fibrillation supraventricular tachycardia [ SVT ] ) Other cardiac pulmonary disease , investigator 's discretion , impair treatment safety Central nervous system ( CNS ) metastases seizure disorder Human immunodeficiency virus ( HIV ) positive test result , history immunodeficiency History organ transplantation History chronic hepatitis B C Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFood Drug Administration [ FDA ] approve indication context research investigation ) Any concurrent medication could interfere trial History tuberculosis history purify protein derivative ( PPD ) positivity Treatment oral/systemic corticosteroid , exception topical inhaled steroid steroid give purpose adrenal replacement give physiologic dos Exposure household contact = &lt; 15 month old household contact know immunodeficiency Allergy measles vaccine history severe reaction prior measles vaccination Allergy iodine ; ( NOTE : include reaction intravenous contrast material ) Any pathology condition principal investigator may deem negatively impact treatment safety On anticoagulation unable discontinue temporarily</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>